Free Trial

Azenta (AZTA) Set to Announce Quarterly Earnings on Tuesday

Azenta logo with Medical background

Azenta (NASDAQ:AZTA - Get Free Report) is scheduled to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Azenta to post earnings of $0.11 per share for the quarter.

Azenta (NASDAQ:AZTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.09. The firm had revenue of $173.00 million for the quarter, compared to analyst estimates of $166.14 million. Azenta had a negative net margin of 23.66% and a positive return on equity of 0.89%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.13 EPS. On average, analysts expect Azenta to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Azenta Stock Performance

Shares of NASDAQ:AZTA traded up $1.11 during midday trading on Tuesday, reaching $46.01. 399,524 shares of the company's stock were exchanged, compared to its average volume of 493,516. The firm has a market capitalization of $2.25 billion, a PE ratio of -16.01 and a beta of 1.48. The company's 50 day simple moving average is $46.22 and its two-hundred day simple moving average is $50.88. Azenta has a 12 month low of $40.24 and a 12 month high of $69.16.

Insider Transactions at Azenta

In related news, CFO Herman Cueto sold 1,595 shares of the firm's stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60. Following the completion of the sale, the chief financial officer now directly owns 24,604 shares of the company's stock, valued at $1,074,702.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.77% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AZTA shares. Evercore ISI lowered their price objective on Azenta from $53.00 to $50.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC reiterated a "buy" rating and set a $69.00 price objective on shares of Azenta in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $66.40.

Get Our Latest Report on AZTA

Azenta Company Profile

(Get Free Report)

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Featured Stories

Earnings History for Azenta (NASDAQ:AZTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Azenta right now?

Before you consider Azenta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.

While Azenta currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines